<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1870">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04526990</url>
  </required_header>
  <id_info>
    <org_study_id>CS-CTP-AD5NCOV-Ⅲ</org_study_id>
    <nct_id>NCT04526990</nct_id>
  </id_info>
  <brief_title>Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above</brief_title>
  <official_title>A Global Multicenter, Randomized, Double-blind, Placebo -Controlled, Adaptive Designed Phase Ⅲ Clinical Trial to Evaluate the Efficacy, Safety and Immunogenicity of Ad5-nCoV in Adults 18 Years of Age and Older</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CanSino Biologics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Institute of Biotechnology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CanSino Biologics Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a global multicenter, randomized, double-blind, placebo -controlled, adaptive
      designed phase Ⅲ clinical trial, in order to evaluate the efficacy, safety and immunogenicity
      of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in adults 18 years old
      and above.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a global phase III clinical trial to evaluate efficacy,safety, immuogenicity of
      Ad5-nCoV manufactured by Cansino and Beijing Institute of Biotechnology in health adults aged
      18 years old and above.

      The study will be double-blind, placebo-controlled trial with participants randomly allocated
      1:1 to placebo and experimental vaccine cohorts.

      The immunization schedule is one doses intramuscular injections (deltoid).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 15, 2020</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 30, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of COVID-19 cases</measure>
    <time_frame>day 28 to 12 months post vaccination</time_frame>
    <description>The efficacy of Ad5-nCoV in preventing virologically confirmed (PCR positive) COVID-19 disease</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of SAE</measure>
    <time_frame>Within 12 months</time_frame>
    <description>Evaluate the incidence of severe adverse events (SAE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of severe COVID-19 cases</measure>
    <time_frame>Day 14 to 12 months post vaccination</time_frame>
    <description>Evaluate the efficacy of Ad5-nCoV in preventing severe COVID-19 disease caused by SARS-CoV-2 infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of solicited adverse reactions</measure>
    <time_frame>Day 0-7 post vaccination</time_frame>
    <description>Incidence of solicited adverse reactions within 7 days after vaccination, in a subset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of unsolicited adverse events</measure>
    <time_frame>Day 0-28 post vaccination</time_frame>
    <description>Incidence of unsolicited adverse events within 28 days after vaccination in a subset</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogencity of S-RBD IgG antibody (ELISA method)</measure>
    <time_frame>Day 28 post vaccination</time_frame>
    <description>The seroconversion rate of S-RBD IgG antibody post vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogencity of neutralizing antibody</measure>
    <time_frame>Day 28 post vaccination</time_frame>
    <description>The seroconversion rate of neutralizing antibody</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-mediated immune profile</measure>
    <time_frame>Day 28 post vaccination</time_frame>
    <description>Number of cell-mediated immune response against SARS-CoV-2</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40000</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20000 participants, Ad5-nCoV , single dose, Intramuscular administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>20000 participants, placebo, single dose, Intramuscular administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)</intervention_name>
    <description>Intramuscular administration</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intramuscular administration</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults of 18 years old and above.

          -  Participants who are at high risk of SARS-CoV-2 infection.

          -  Able and willing (in the Investigator's opinion) to comply with all study
             requirements.

          -  Willing to allow the investigators to discuss the volunteer's medical history with
             their General Practitioner/personal doctor and access all medical records when
             relevant to study procedures.

          -  Agreement to refrain from blood donation during the study.

          -  provide written informed consent.

        Exclusion Criteria:

          -  Participation in any other COVID-19 prophylactic drug trials for the duration of the
             study.

          -  Participation in SARS-CoV-2 serological surveys where participants are informed of
             their serostatus for the duration of the study.

          -  Planned receipt of any vaccine (licensed or investigational), other than the study
             intervention, within 14 days before and after study vaccination.

          -  Prior receipt of an investigational or licensed vaccine likely to impact on the
             interpretation of the trial data.

          -  Administration of immunoglobulins and/or any blood products within the three months
             prior to the planned administration of the vaccine candidate.

          -  Planned receipt of any vaccine (licensed or investigational), other than the study
             intervention, within 14 days before and after study vaccination

          -  Prior receipt of an investigational or licensed vaccine likely to impact on the
             interpretation of the trial data (e.g. Adenovirus vectored vaccines, any coronavirus
             or SARS vaccines)

          -  Administration of immunoglobulins and/or any blood products within the three months
             prior to the planned administration of the vaccine candidate

          -  Any confirmed or suspected immunosuppressive or immunodeficient state; positive HIV
             status; asplenia; recurrent severe infections and chronic use.

          -  History of allergic disease or reactions likely to be exacerbated by any component of
             Ad5-nCoV

          -  Any history of angioedema

          -  Any history of anaphylaxis to any vaccine component

          -  Pregnancy, lactation or willingness/intention to become pregnant during the study

          -  Current diagnosis of or treatment for cancer (except basal cell carcinoma of the skin
             and cervical carcinoma in situ)

          -  History of serious psychiatric condition likely to affect participation in the study

          -  Suspected or known current alcohol or drug dependency

          -  Severe and/or uncontrolled cardiovascular disease, respiratory disease,
             gastrointestinal disease, liver disease, renal disease, endocrine disorder and
             neurological illness

          -  History of laboratory-confirmed COVID-19

          -  Any other significant disease, disorder or finding which may significantly increase
             the risk to the volunteer because of participation in the study, affect the ability of
             the volunteer to participate in the study or impair interpretation of the study data.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott A Halperin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Canadian Center for Vaccinology</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fengcai Zhu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jiangsu Provincial Center for Disease Control and Prevention</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joanne M angley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Canadian Center for Vaccinology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinbo Gou, MD</last_name>
    <phone>+86-022-58213600-6051</phone>
    <email>jinbo.gou@cansinotech.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shaukat Khanum Memorial Cancer Hospital and Research Centre</name>
      <address>
        <city>Islamabad</city>
        <state>Norhern Punajb Rawalpindi</state>
        <zip>30001</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aamer Ikram SI, phD</last_name>
      <phone>+923215170713</phone>
      <email>maahin1@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Aamer Ikram SI, phD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 22, 2020</study_first_submitted>
  <study_first_submitted_qc>August 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2020</study_first_posted>
  <last_update_submitted>September 15, 2020</last_update_submitted>
  <last_update_submitted_qc>September 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>vaccine</keyword>
  <keyword>Ad5</keyword>
  <keyword>Safety</keyword>
  <keyword>Immunogencity</keyword>
  <keyword>efficacy</keyword>
  <keyword>adaptive design</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Adenovirus Vector</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

